Ovid Therapeutics Inc. (OVID) 의 후행 P/E가 마이너스 -13.6, 이는 회사가 현재 후행 12개월(TTM) 기준으로 적자 상태임을 의미합니다. 후행 이익수익률은 -7.38%.
이 페이지에서 입증된 기준:
SharesGrow 종합 점수: 51/100 2/7 개 기준 통과.
| Year | P/E (TTM) | PEG 비율 | P/B 비율 | P/S 비율 | 배당 수익률 |
|---|---|---|---|---|---|
| 2016 | -10.7 | -0.15 | 4.87 | 0.00 | - |
| 2017 | -2.9 | -0.02 | 2.29 | 0.00 | - |
| 2018 | -1.1 | 0.03 | 1.54 | 0.00 | - |
| 2019 | -2.7 | 0.09 | 2.32 | 0.00 | - |
| 2020 | -1.7 | 0.21 | 3.09 | 10.70 | - |
| 2021 | 1.8 | -0.01 | 1.21 | 1.04 | - |
| 2022 | -2.4 | 0.02 | 0.99 | 87.17 | - |
| 2023 | -4.3 | 1.11 | 2.59 | 579.77 | - |
| 2024 | -2.5 | 0.05 | 0.97 | 116.97 | - |
| 2025 | -6.9 | 0.20 | 0.92 | 16.57 | - |
| Year | EPS (희석) | 매출 | 순이익 | 순이익률 |
|---|---|---|---|---|
| 2016 | $-1.14 | $0.00 | $-22.41M | - |
| 2017 | $-3.35 | $0.00 | $-64.81M | - |
| 2018 | $-2.11 | $0.00 | $-51.98M | - |
| 2019 | $-1.51 | $0.00 | $-60.46M | - |
| 2020 | $-1.39 | $12.62M | $-81.04M | -642.3% |
| 2021 | $1.76 | $208.38M | $122.84M | 58.9% |
| 2022 | $-0.77 | $1.5M | $-54.17M | -3604.1% |
| 2023 | $-0.74 | $391.7K | $-52.34M | -13362.2% |
| 2024 | $-0.37 | $566K | $-26.43M | -4670.1% |
| 2025 | $-0.24 | $7.25M | $-17.41M | -240.1% |
| Year | EPS (평균) | EPS 범위 | 매출 (평균) | 매출 범위 | 애널리스트 수 |
|---|---|---|---|---|---|
| 2026 | $-0.50 | $-1.08 – $-0.28 | $254.38K | $86.04K – $415.23K | 8 |
| 2027 | $-0.63 | $-1.35 – $-0.39 | $226.67K | $83.33K – $370K | 6 |
| 2028 | $-0.75 | $-1.40 – $-0.41 | $282K | $99.53K – $460.32K | 6 |
| 2029 | $-0.68 | $-1.24 – $-0.11 | $10.8M | $3.81M – $17.63M | 4 |
| 2030 | $-0.17 | $-0.32 – $-0.03 | $71.62M | $25.28M – $116.91M | 2 |
